P5‐106: Japanese, multicenter, phase II trial of combination therapy with favipiravir and methylprednisolone for COVID‐19 patients with non‐critical respiratory failure: the J‐critical trial

lymphocytopenia compared to those with mild-moderate degree. Platelet Lymphocyte Ratio (PLR) is a marker of inflammation for predicting severity and death in COVID-19. This study assessed the relationship between platelet count, lymphocyte count, and PLR with severity of disease in COVID-19 patients admitted at Dr. Saiful Anwar Malang Hospital. Method: Observational analysis with a cross sectional approach in 59 confirmed COVID-19 patients admitted in the Dr. Saiful Anwar Malang Hospital between April May 2020. Statistical analysis was performed by using the T test for numerical variables. Result: There were 38 patients (64%) with severe degree and 21 patients (36%) with mild to moderate degree. It was found that the mean value of platelets in patients with severe was lower than in patients with mild to moderate (250236.84 94887 vs 281619.05 94169), but it was not statistically significant (p = 0.288). Lymphocyte mean in patients with severe was lower than in patients with mild (1067.63 430.96 vs 1708.3 1370) but it was not statistically significant (p = 0.053). The mean PLR in patients with severe was 306.2 379.21, while in patients with mildmoderate it was 206.21 88.22, but it was not statistically significant (p = 0.106). Conclusion: There is a decrease in platelets and lymphocyte count, and an increase in PLR in patients with severe COVID-19, although not statistically significant.